Comparing two mapping catheters during ablation for atrial fibrillation
Compares Optrell and Octaray catheters for confirming ablation lines in adults with atrial fibrillation.
Plain-language title generated from the registry record
Registry title: Comparative Evaluation of Optrell and Octaray Mapping Catheters for Conduction Block Confirmation and Voltage Assessment During Atrial Ablation
Key facts
- Where
- Be’er Ya‘aqov, IsraelSee the site
Where in Israel
- Shamir Medical CenterBe’er Ya‘aqov, IsraelTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Maxime Zabern
- Trial code
- NCT07563257
- Record updated
- 3 June 2026
- Original description
This prospective, single-center observational study aims to compare the clinical performance, workflow efficiency, and electrophysiological metrics of two commercially available, high-density multielectrode mapping catheters (Octaray and Optrell) in patients undergoing catheter ablation for complex atrial arrhythmias.Read full original descriptionShow less
Comparative Evaluation of Optrell and Octaray Mapping Catheters for Conduction Block Confirmation and Voltage Assessment During Atrial Ablation
This prospective, single-center observational study aims to compare the clinical performance, workflow efficiency, and electrophysiological metrics of two commercially available, high-density multielectrode mapping catheters (Octaray and Optrell) in patients undergoing catheter ablation for complex atrial arrhythmias.
The primary focus is to determine if the real-time vector propagation capabilities of the Optrell catheter combined with V8 software can accurately confirm conduction block across linear ablation lesions without the need for full-chamber activation remapping, which is the current standard of care. A secondary focus will pair-compare the bipolar voltage amplitude distributions recorded by both catheters, given their differing electrode sizes and spacing.
Inclusion: • Age ≥18 years; • Documented persistent atrial fibrillation and/or atrial flutter; • Undergoing a clinically indicated first-time (de novo) or redo catheter ablation where linear ablation lesion sets (e.g., posterior wall, roof line, lateral mitral line, CTI) are planned or anticipated; • Ability to provide written informed consent.
Exclusion: • Any medical condition or anatomical contraindication that, in the investigator's judgment, precludes safe participation; • Paroxysmal or persistent AF where only standard PVI is planned; • Mechanical mitral valve; • Presence of intracardiac thrombus or contraindication to systemic anticoagulation; • Pregnant women.